Drug evaluation: the C5a receptor antagonist PMX-53

Curr Opin Mol Ther. 2006 Dec;8(6):529-38.

Abstract

Peptech is developing PMX-53, a complement C5a inhibitor for the potential treatment of inflammatory disorders, including rheumatoid arthritis and psoriasis. Phase Ib/IIa clinical trials have been completed for both indications.

Publication types

  • Review

MeSH terms

  • Animals
  • Antigen-Antibody Complex / drug effects
  • Arthritis, Rheumatoid / drug therapy
  • Arthritis, Rheumatoid / immunology
  • Clinical Trials, Phase I as Topic
  • Clinical Trials, Phase II as Topic
  • Complement Inactivating Agents / chemical synthesis
  • Complement Inactivating Agents / chemistry
  • Complement Inactivating Agents / pharmacology
  • Drug Evaluation, Preclinical
  • Humans
  • In Vitro Techniques
  • Inflammation / drug therapy
  • Inflammation / immunology
  • Inflammatory Bowel Diseases / drug therapy
  • Inflammatory Bowel Diseases / immunology
  • Macular Degeneration / drug therapy
  • Macular Degeneration / immunology
  • Membrane Proteins / antagonists & inhibitors*
  • Nerve Degeneration / drug therapy
  • Nerve Degeneration / immunology
  • Peptides, Cyclic / chemical synthesis
  • Peptides, Cyclic / chemistry
  • Peptides, Cyclic / pharmacology
  • Receptor, Anaphylatoxin C5a / antagonists & inhibitors
  • Receptors, Complement / antagonists & inhibitors*
  • Structure-Activity Relationship

Substances

  • Antigen-Antibody Complex
  • C5AR1 protein, human
  • Complement Inactivating Agents
  • Membrane Proteins
  • Peptides, Cyclic
  • Receptor, Anaphylatoxin C5a
  • Receptors, Complement